{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T05:57:29Z","timestamp":1725515849362},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,12,15]],"date-time":"2011-12-15T00:00:00Z","timestamp":1323907200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s10067-011-1902-3","type":"journal-article","created":{"date-parts":[[2011,12,14]],"date-time":"2011-12-14T04:45:23Z","timestamp":1323837923000},"page":"203-210","source":"Crossref","is-referenced-by-count":13,"title":["Is continuation of anti-tumor necrosis factor-\u03b1 therapy a safe option for patients who have developed pulmonary mycobacterial infection?"],"prefix":"10.1007","volume":"31","author":[{"given":"Shunsuke","family":"Mori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mineharu","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,12,15]]},"reference":[{"key":"1902_CR1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","volume":"38","author":"RS Wallis","year":"2004","unstructured":"Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261\u20131265","journal-title":"Clin Infect Dis"},{"key":"1902_CR2","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1086\/587989","volume":"46","author":"KL Winthrop","year":"2008","unstructured":"Winthrop KL, Yamashita S, Beekmann SE, Polgreen PM (2008) Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the emerging infections network. Clin Infect Dis 46:1738\u20131740","journal-title":"Clin Infect Dis"},{"key":"1902_CR3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10165-007-0626-3","volume":"17","author":"R Koike","year":"2007","unstructured":"Koike R, Takeuchi T, Eguchi K, Miyasaka N (2007) Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 17:451\u2013458","journal-title":"Mod Rheumatol"},{"key":"1902_CR4","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","volume":"36","author":"I Solovic","year":"2010","unstructured":"Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ et al (2010) The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 36:1185\u20131206","journal-title":"Eur Respir J"},{"key":"1902_CR5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/ncprheum0949","volume":"4","author":"J Ingen van","year":"2008","unstructured":"van Ingen J, Boeree MJ, Dekhuijzen PN, van Soolingen D (2008) Mycobacterial disease in patients with rheumatic disease. Nat Clin Pract Rheumatol 4:649\u2013656","journal-title":"Nat Clin Pract Rheumatol"},{"key":"1902_CR6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"DE Griffith","year":"2007","unstructured":"Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F et al (2007) An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175:367\u2013416","journal-title":"Am J Respir Crit Care Med"},{"key":"1902_CR7","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"KG Saag","year":"2008","unstructured":"Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR et al (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762\u2013784","journal-title":"Arthritis Rheum"},{"key":"1902_CR8","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/rheumatology\/keh700","volume":"44","author":"I Marie","year":"2005","unstructured":"Marie I, Heliot P, Roussel F, Herve F, Muir JF, Levesque H (2005) Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab. Rheumatology (Oxford) 44:1201\u20131202","journal-title":"Rheumatology (Oxford)"},{"key":"1902_CR9","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1136\/thx.2005.056952","volume":"62","author":"N Maimon","year":"2007","unstructured":"Maimon N, Brunton J, Chan AK, Marras TK (2007) Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept. Thorax 62:739\u2013740","journal-title":"Thorax"},{"key":"1902_CR10","first-page":"12","volume":"65","author":"JE Thomas","year":"2006","unstructured":"Thomas JE, Taoka CR, Gibbs BT, Fraser SL (2006) Fatal pulmonary Mycobacterium abscessus infection in a patient using etanercept. Hawaii Med J 65:12\u201315","journal-title":"Hawaii Med J"},{"key":"1902_CR11","first-page":"705","volume":"29","author":"E Besada","year":"2011","unstructured":"Besada E (2011) Rapid growing mycobacteria and TNFalpha blockers: case report of a fatal lung infection with Mycobacterium abscessus in a patient treated with infliximab, and literature review. Clin Exp Rheumatol 29:705\u2013707","journal-title":"Clin Exp Rheumatol"},{"key":"1902_CR12","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jinf.2007.08.007","volume":"55","author":"EM Salvana","year":"2007","unstructured":"Salvana EM, Cooper GS, Salata RA (2007) Mycobacterium other than tuberculosis (MOTT) infection: an emerging disease in infliximab-treated patients. J Infect 55:484\u2013487","journal-title":"J Infect"},{"key":"1902_CR13","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.3201\/eid1510.090110","volume":"15","author":"RM Swart","year":"2009","unstructured":"Swart RM, van Ingen J, van Soolingen D, Slingerland R, Hendriks WD, den Hollander JG (2009) Nontuberculous mycobacteria infection and tumor necrosis factor-alpha antagonists. Emerg Infect Dis 15:1700\u20131701","journal-title":"Emerg Infect Dis"},{"key":"1902_CR14","first-page":"312","volume":"48","author":"T Esaki","year":"2010","unstructured":"Esaki T, Sugimoto M, Mori S, Yamashita A, Matsumoto M, Kohrogi H (2010) A case of pulmonary nontuberculous mycobacteriosis aggravated during treatment with etanercept for rheumatoid arthritis. Nihon Kokyuki Gakkai Zasshi 48:312\u2013316","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"1902_CR15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s10165-004-0360-z","volume":"15","author":"H Okubo","year":"2005","unstructured":"Okubo H, Iwamoto M, Yoshio T, Okazaki H, Kato T, Bandoh M et al (2005) Rapidly aggravated Mycobacterium avium infection in a patient with rheumatoid arthritis treated with infliximab. Mod Rheumatol 15:62\u201364","journal-title":"Mod Rheumatol"},{"key":"1902_CR16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jinf.2008.04.010","volume":"57","author":"A Martin-Aspas","year":"2008","unstructured":"Martin-Aspas A, Guerrero-Sanchez F, Garcia-Martos P, Gonzalez-Moya E, Medina-Varo F, Giron Gonzalez JA (2008) Bilateral pneumonia by Mycobacterium aurum in a patient receiving infliximab therapy. J Infect 57:167\u2013169","journal-title":"J Infect"},{"key":"1902_CR17","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/ncprheum0538","volume":"3","author":"J Ingen van","year":"2007","unstructured":"van Ingen J, Boeree M, Janssen M, Ullmann E, de Lange W, de Haas P et al (2007) Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. Nat Clin Pract Rheumatol 3:414\u2013419","journal-title":"Nat Clin Pract Rheumatol"},{"key":"1902_CR18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00128071-200708060-00009","volume":"8","author":"E Rallis","year":"2007","unstructured":"Rallis E, Koumantaki-Mathioudaki E, Frangoulis E, Chatziolou E, Katsambas A (2007) Severe sporotrichoid fish tank granuloma following infliximab therapy. Am J Clin Dermatol 8:385\u2013388","journal-title":"Am J Clin Dermatol"},{"key":"1902_CR19","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/00365540310017474","volume":"36","author":"K Yim","year":"2004","unstructured":"Yim K, Nazeer SH, Kiska D, Rose FB, Brown D, Cynamon MH (2004) Recurrent Mycobacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept. Scand J Infect Dis 36:150\u2013154","journal-title":"Scand J Infect Dis"},{"key":"1902_CR20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00124743-200210000-00007","volume":"8","author":"N Chopra","year":"2002","unstructured":"Chopra N, Kirschenbaum AE, Widman D (2002) Mycobacterium marinum tenosynovitis in a patient on etanercept therapy for rheumatoid arthritis. J Clin Rheumatol 8:265\u2013268","journal-title":"J Clin Rheumatol"},{"key":"1902_CR21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/art.24095","volume":"61","author":"JA Dare","year":"2009","unstructured":"Dare JA, Jahan S, Hiatt K, Torralba KD (2009) Reintroduction of etanercept during treatment of cutaneous Mycobacterium marinum infection in a patient with ankylosing spondylitis. Arthritis Rheum 61:583\u2013586","journal-title":"Arthritis Rheum"},{"key":"1902_CR22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/09273940600678062","volume":"14","author":"MW Stewart","year":"2006","unstructured":"Stewart MW, Alvarez S, Ginsburg WW, Shetty R, McLain WC, Sleater JP (2006) Visual recovery following Mycobacterium chelonae endophthalmitis. Ocul Immunol Inflamm 14:181\u2013183","journal-title":"Ocul Immunol Inflamm"},{"key":"1902_CR23","first-page":"914","volume":"10","author":"MB Chang","year":"2011","unstructured":"Chang MB, Sri JC, Driscoll M, Gaspari AA (2011) Mycobacterium fortuitum infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF-a blockers. J Drugs Dermatol 10:914\u2013916","journal-title":"J Drugs Dermatol"},{"key":"1902_CR24","first-page":"101","volume":"28","author":"N Kluger","year":"2010","unstructured":"Kluger N, Cohen P, Fallet-Bianco C, Guillevin L (2010) Mycobacterium chelonae infection under adalimumab therapy for spondylarthritis. Clin Exp Rheumatol 28:101\u2013102","journal-title":"Clin Exp Rheumatol"},{"key":"1902_CR25","first-page":"43","volume":"33","author":"JC Fallon","year":"2008","unstructured":"Fallon JC, Patchett S, Gulmann C, Murphy GM (2008) Mycobacterium marinum infection complicating Crohn\u2019s disease, treated with infliximab. Clin Exp Dermatol 33:43\u201345","journal-title":"Clin Exp Dermatol"},{"key":"1902_CR26","first-page":"723","volume":"24","author":"N Boulman","year":"2006","unstructured":"Boulman N, Rozenbaum M, Slobodin G, Rosner I (2006) Mycobacterium fortuitum infection complicating infliximab therapy in rheumatoid arthritis. Clin Exp Rheumatol 24:723","journal-title":"Clin Exp Rheumatol"},{"key":"1902_CR27","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/00365540902774599","volume":"41","author":"JR Danko","year":"2009","unstructured":"Danko JR, Gilliland WR, Miller RS, Decker CF (2009) Disseminated Mycobacterium marinum infection in a patient with rheumatoid arthritis receiving infliximab therapy. Scand J Infect Dis 41:252\u2013255","journal-title":"Scand J Infect Dis"},{"key":"1902_CR28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1099\/jmm.0.017277-0","volume":"59","author":"JM Ramos","year":"2010","unstructured":"Ramos JM, Garcia-Sepulcre MF, Rodriguez JC, Padilla S, Gutierrez F (2010) Mycobacterium marinum infection complicated by anti-tumour necrosis factor therapy. J Med Microbiol 59:617\u2013621","journal-title":"J Med Microbiol"},{"key":"1902_CR29","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.3899\/jrheum.090056","volume":"36","author":"AA Elyousfi","year":"2009","unstructured":"Elyousfi AA, Leiter JR, Goytan MJ, Robinson DB (2009) Mycobacterium heckeshornense lumbar spondylodiskitis in a patient with rheumatoid arthritis receiving etanercept treatment. J Rheumatol 36:2130\u20132131","journal-title":"J Rheumatol"},{"key":"1902_CR30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.diagmicrobio.2005.06.006","volume":"53","author":"AH Mufti","year":"2005","unstructured":"Mufti AH, Toye BW, McKendry RR, Angel JB (2005) Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use. Diagn Microbiol Infect Dis 53:233\u2013238","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1902_CR31","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1099\/jmm.0.006809-0","volume":"58","author":"J Malkin","year":"2009","unstructured":"Malkin J, Shrimpton A, Wiselka M, Barer MR, Duddridge M, Perera N (2009) Olecranon bursitis secondary to Mycobacterium kansasii infection in a patient receiving infliximab for Behcet\u2019s disease. J Med Microbiol 58:371\u2013373","journal-title":"J Med Microbiol"},{"key":"1902_CR32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5070\/D33NH337N8","volume":"14","author":"JM Shehan","year":"2008","unstructured":"Shehan JM, Sarma DP (2008) Mycobacterium mucogenicum: report of a skin infection associated with etanercept. Dermatol Online J 14:5","journal-title":"Dermatol Online J"},{"key":"1902_CR33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/03009740701716876","volume":"37","author":"F Diaz","year":"2008","unstructured":"Diaz F, Urkijo JC, Mendoza F, de la Viuda JM, Blanco M, Unzurrunzaga A et al (2008) Mycobacterium chelonae infection associated with adalimumab therapy. Scand J Rheumatol 37:159\u2013160","journal-title":"Scand J Rheumatol"},{"key":"1902_CR34","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhsa.2009.09.018","volume":"35","author":"AS Bauer","year":"2010","unstructured":"Bauer AS, Blazar PE, Earp BE, Simmons BP (2010) Mycobacterial hand infections occurring postoperatively in patients treated with tumor necrosis factor-alpha inhibitors for inflammatory arthritis: report of three cases. J Hand Surg Am 35:104\u2013108","journal-title":"J Hand Surg Am"},{"key":"1902_CR35","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1093\/rheumatology\/keq146","volume":"49","author":"C Garzoni","year":"2010","unstructured":"Garzoni C, Adler S, Boller C, Furrer H, Villiger PM (2010) Possible role of anti-TNF monoclonal antibodies in the treatment of Mycobacterium marinum infection. Rheumatology (Oxford) 49:1991\u20131993","journal-title":"Rheumatology (Oxford)"},{"key":"1902_CR36","first-page":"144","volume":"66","author":"S Steyaert","year":"2011","unstructured":"Steyaert S, Stappaerts G, Mareen P, Dierick J (2011) Soft tissue infections with atypical mycobacteria in two patients with inflammatory rheumatic diseases using TNF-inhibitors and\/or leflunomide. Acta Clin Belg 66:144\u2013147","journal-title":"Acta Clin Belg"},{"key":"1902_CR37","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1097\/DAD.0b013e3182120ae3","volume":"33","author":"I Yeh","year":"2011","unstructured":"Yeh I, Evan G, Jokinen CH (2011) Cutaneous mycobacterial spindle cell pseudotumor: a potential mimic of soft tissue neoplasms. Am J Dermatopathol 33:e66\u2013e69","journal-title":"Am J Dermatopathol"},{"key":"1902_CR38","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/ibd.21512","volume":"17","author":"BG Levesque","year":"2011","unstructured":"Levesque BG, Sandborn WJ (2011) Mycobacterium marinum infection in the setting of antitumor necrosis factor alpha therapy for Crohn\u2019s disease. Inflamm Bowel Dis 17:1443\u20131444","journal-title":"Inflamm Bowel Dis"},{"key":"1902_CR39","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/430914","volume":"41","author":"RS Wallis","year":"2005","unstructured":"Wallis RS (2005) Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 41:201\u2013208","journal-title":"Clin Infect Dis"},{"key":"1902_CR40","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1086\/522993","volume":"45","author":"SM Arend","year":"2007","unstructured":"Arend SM, Leyten EM, Franken WP, Huisman EM, van Dissel JT (2007) A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 45:1470\u20131475","journal-title":"Clin Infect Dis"},{"key":"1902_CR41","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1086\/427941","volume":"40","author":"C Garcia Vidal","year":"2005","unstructured":"Garcia Vidal C, Rodriguez Fernandez S, Martinez Lacasa J, Salavert M, Vidal R, Rodriguez Carballeira M et al (2005) Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 40:756\u2013759","journal-title":"Clin Infect Dis"},{"key":"1902_CR42","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1086\/598504","volume":"48","author":"RS Wallis","year":"2009","unstructured":"Wallis RS, van Vuuren C, Potgieter S (2009) Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 48:1429\u20131432","journal-title":"Clin Infect Dis"},{"key":"1902_CR43","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1086\/592695","volume":"47","author":"TK Blackmore","year":"2008","unstructured":"Blackmore TK, Manning L, Taylor WJ, Wallis RS (2008) Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 47:e83\u2013e85","journal-title":"Clin Infect Dis"},{"key":"1902_CR44","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/art.23210","volume":"58","author":"S Aslanidis","year":"2008","unstructured":"Aslanidis S, Pyrpasopoulou A, Douma S, Petidis K (2008) Is it safe to readminister tumor necrosis factor alpha antagonists following tuberculosis flare? Arthritis Rheum 58:327\u2013328","journal-title":"Arthritis Rheum"},{"key":"1902_CR45","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMc053468","volume":"355","author":"T Matsumoto","year":"2006","unstructured":"Matsumoto T, Tanaka T, Kawase I (2006) Infliximab for rheumatoid arthritis in a patient with tuberculosis. N Engl J Med 355:740\u2013741","journal-title":"N Engl J Med"},{"key":"1902_CR46","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1469-0691.2007.01891.x","volume":"14","author":"B Denis","year":"2008","unstructured":"Denis B, Lefort A, Flipo RM, Tubach F, Lemann M, Ravaud P et al (2008) Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment. Clin Microbiol Infect 14:183\u2013186","journal-title":"Clin Microbiol Infect"},{"key":"1902_CR47","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3201\/eid1510.090310","volume":"15","author":"KL Winthrop","year":"2009","unstructured":"Winthrop KL, Chang E, Yamashita S, Iademarco MF, LoBue PA (2009) Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 15:1556\u20131561","journal-title":"Emerg Infect Dis"},{"key":"1902_CR48","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1378\/chest.07-0358","volume":"133","author":"J Glassroth","year":"2008","unstructured":"Glassroth J (2008) Pulmonary disease due to nontuberculous mycobacteria. Chest 133:243\u2013251","journal-title":"Chest"},{"key":"1902_CR49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1378\/chest.102.1.89","volume":"102","author":"S Yamori","year":"1992","unstructured":"Yamori S, Tsukamura M (1992) Comparison of prognosis of pulmonary diseases caused by Mycobacterium avium and by Mycobacterium intracellulare. Chest 102:89\u201390","journal-title":"Chest"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-011-1902-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-011-1902-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-011-1902-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T01:23:52Z","timestamp":1639963432000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-011-1902-3"}},"subtitle":["Case presentation and literature review"],"short-title":[],"issued":{"date-parts":[[2011,12,15]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["1902"],"URL":"https:\/\/doi.org\/10.1007\/s10067-011-1902-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,15]]}}}